Clinical Trial Update: A Study on the Use of Fluzoparib Combined With Chemotherapy for Neoadjuvant Treatment of HRD-positive, HR+/HER2- Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Fluzoparib plus chemotherapy as neoadjuvant therapy for HRD-positive, hormone receptor-positive/HER2-negative breast cancer; trial comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• Fluzoparib (fluzoparib)

Snippet

Sponsor: Xijing Hospital | Conditions: HR+/HER2- Early Breast Cancer | Phase 2 | Status: COMPLETED